Our focus in the past three years was to get real clinical data on our formulations from physicians in America, while continuously improving our sales and service model for our customers to achieve over 70% retention on our products for over 18 months.
Past News ReleasesRSS
Whitehouse Station, NJ (PRWEB) February 2, 2010
PreEmptive Meds, Inc. announces the return of Charles N. Blitzer as Chief Executive Officer.
Along with Dr. Joe Fenn, Mr. Blitzer co-founded PreEmptive Meds, Inc. (PMI) and served as Chief Executive Officer from late 2006 until June 2008. The company has pioneered the promotion of branded, proprietary, all natural, nutraceutical formulations directly to Primary Care Physicians for various pre-disease conditions such as diabetes (PreCrea®), elevated cholesterol and lipids (PreLipid® and PreLipid® Plus), symptoms associated with perimenopause (PreMenora® and PreMenora® Plus), and arthritis symptoms of joint pain and inflammation (PreArthros® and Pre Arthros® Plus). Physician promotion is conducted directly to Primary Care Physicians with a pharmaceutical based sales force comprising seasoned sales associates familiar with the Primary Care Physician community.
Charles N. Blitzer – Chief Executive Officer:
Mr. Blitzer has over 25 years of senior level experience within the pharmaceutical industry, including legal (both general corporate and intellectual property), business development, strategic planning and operations. During his tenure at Marion Laboratories, Inc., a Fortune 500 company, he was involved with the in-licensing of four prescription drugs which collectively reached $1 billion in sales. While at Marion Laboratories, he was also responsible for the in-licensing and ultimate acquisition of the over-the-counter antacid Gaviscon®, which became a big success through direct promotion to the physician as was Marion’s Os-Cal® brand of calcium. Mr. Blitzer also played a key role in the merger between Marion and Merrell Dow Pharmaceuticals, which eventually became part of Sanofi-Aventis Pharmaceuticals.
As Chief Executive Officer of MGI Pharma, Inc., a publicly traded oncology company, Mr. Blitzer saw its market cap grow from $42 million to over $1 billion before his retirement in 2003. MGI Pharma has since been acquired by Eisai Pharmaceuticals.
Since 2003, Mr. Blitzer has served as executive advisor and/or temporary CEO to several start-up and development-stage life science companies. Mr. Blitzer served as the company’s initial Chief Executive Officer until June 2008, while remaining an active member of its board of directors.
Mr. Blitzer holds a B.S. degree in Pharmacy from the University of Toledo, a J.D. degree from American University and an M.B.A. from Rockhurst College.
“We are extremely pleased to have Mr. Blitzer return to the Company as its Chief Executive Officer,” stated Dr. Joe Fenn, Chairman and President. In the last three years, over 1500 physicians in the US have used the Company’s products successfully on over 200,000 patient experiences. “His broad based experience within the pharmaceutical sector and with the financial community will serve our company well as we move toward our next level of growth.”
PreEmptive Meds, Inc., is poised for growth with increased acceptance of its products in the Primary Care Physician community. As more and more physicians experience measurable clinical improvements with the Company’s products and with the excellent safety profile of the products, the Company is investing in growth and has plans to expand sales to Primary Care Physicians in 20 States in 2010.
“Our focus in the past three years was to get real clinical data on our formulations from physicians in America, while continuously improving our sales and service model for our customers to achieve over 70% retention on our products for over 18 months. I think we have accomplished that with independently reported clinical evidence of over 80% efficacy of our formulations in over 200,000 patient experiences in America for the past three years," stated Dr. Joe Fenn.
With favorable clinical data on its products equal to the best in class prescription drugs, the Company has introduced a 100% Money back guarantee on its products and also offers its products on a risk-free trial basis to all new customers for three months. This risk-free trial period allows physicians to try these clinically proven formulations on their patients and test the efficacy on each patient, without any financial risk for their patients. PreEmptive Meds, Inc., is the only Pharmaceutical or Nutraceutical Company in America to make such an offer.
“We know that our products do not work efficaciously for everyone and therefore, we believe that it’s only fair that those individuals on who our products do not achieve the desired clinical result should not have to pay. We want physicians to have effective and safe clinical options for their patients, while taking away any financial risk for their patients,” stated Dr. Joe Fenn.
PreEmptive Meds is a pre-disease focused, all natural, Nutraceutical company, promoting its proprietary branded products directly to the Primary Care Physician community.
Joe Fenn, M.D.
Chairman & President
PreEmptive Meds, Inc.